Keryx Biopharmaceuticals (NASDAQ:KERX): The mean short term price target for Keryx Biopharmaceuticals (NASDAQ:KERX) has been established at $8.75 per share. The higher price target estimate is at $13 and the lower price target estimate is expected at $4 according to 8 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $2.92
Many analysts have stated their opinion on the company shares. Equity analysts at the Brokerage firm Maxim Group maintains its rating on Keryx Biopharmaceuticals (NASDAQ:KERX). The rating major has initiated the coverage with buy rating on the shares. The Analysts at Maxim Group raises the price target from $5 per share to $7 per share. The rating by the firm was issued on March 29, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, The director officer (President and CEO), of Keryx Biopharmaceuticals Inc, Madison Greg had unloaded 1,873 shares at $5.42 per share in a transaction on May 9, 2016. The total value of transaction was $10,152. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Keryx Biopharmaceuticals (NASDAQ:KERX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.07 points or 1.18% at $5.86 with 1,484,448 shares getting traded. Post opening the session at $5.86, the shares hit an intraday low of $5.71 and an intraday high of $5.93 and the price was in this range throughout the day. The company has a market cap of $620 million and the number of outstanding shares have been calculated to be 105,820,947 shares. The 52-week high of Keryx Biopharmaceuticals (NASDAQ:KERX) is $10.51 and the 52-week low is $2.8.
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).